Une étude suggère qu'il n'y a pas de risque d'hémorragies en utilisant en même temps, le nilotinib (Tasigna) et le wafarin (Coumadin)
Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin.
Author(s): O. Yin, N. J. Gallagher, D. Fischer, L. Zhao, W. Zhou, G. Golor, H. Schran; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Parexel International GmbH, Berlin, Germany - 2009 ASCO Annual Meeting, Abstract No: 7063
'Conclusion: The study results demonstrate a lack of effect of nilotinib on the PK and PD of warfarin, suggesting nilotinib does not inhibit CYP2C9 activity in human subjects. These findings suggest that warfarin can be used with nilotinib concurrently without the risk of bleeding'
http://abstract.asco.org/AbstView_65_31547.html